BioMedNewsBreaks — Astrotech Corporation’s (NASDAQ: ASTC) Breakthrough TRACER 1000(TM) Designed to Outperform Currently Used IMS Detectors

Astrotech (NASDAQ: ASTC) is a mass spectrometry company that, through its wholly owned subsidiary 1st Detect, has developed and rolled out the breakthrough TRACER 1000(TM) Explosive Trace Detector (“ETD”). “The world’s first mass spectrometry-based ETD certified by the European Civil Aviation Conference (‘ECAC’), the TRACER 1000(TM) is designed to outperform the ETDs currently used at aviation checkpoints as well as borders, cargo facilities and other secured points around the world. It is powered by the Astrotech Mass Spectrometer (‘AMS’) Technology that is inexpensive, smaller and easier to use when compared to traditional mass spectrometers. The AMS Technology works under ultra-high vacuum, which eliminates competing molecules, resulting in higher resolution and fewer false alarms,” a recent article reads. “Astrotech nonetheless believes that ETD customers are unsatisfied with the currently deployed ETD technology, which is driven by ion mobility spectrometry (‘IMS’)… Against this backdrop and as many of the tens of thousands of IMS instruments deployed in the field near their end of life and need replacement, Astrotech is working to position its TRACER 1000(TM) product as the next-generation solution for the ETD market. ‘Based on our near-zero false alarm rate, we believe that the TRACER 1000(TM) improves checkpoint efficiency and passenger throughput by reducing the need for time-consuming and invasive secondary screenings that cost airports millions in lost merchandise and food sales,’ said Thomas B. Pickens III, chairman and CEO of 1st Detect.”

To view the full article, visit https://ibn.fm/VeYWM

About Astrotech Corporation

Astrotech is an innovative science and technology company that invents, acquires and commercializes technological innovations while building scalable companies to maximize shareholder value. For more information, please visit www.AstrotechCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to ASTC are available in the company’s newsroom at https://ibn.fm/ASTC

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN